MBX Biosciences Inc
MBX25.451USD
+0.541+2.17%
交易中 （美东）报价延迟15分钟
1.14B总市值
亏损市盈率 TTM
关于 MBX Biosciences Inc 公司
MBX Biosciences, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现和开发用于治疗内分泌和代谢紊乱的新型精准肽疗法。该公司已建立其专有的精准内分泌肽平台，以开发旨在克服当前肽疗法关键限制的精准肽疗法。其候选产品和项目包括 MBX 2109、MBX 1416 和肥胖产品组合。MBX 2109 是一种甲状旁腺激素肽前药，旨在作为一种潜在的长效激素替代疗法，用于治疗慢性甲状旁腺功能减退症。MBX 1416 旨在成为一种长效胰高血糖素样肽-1 (GLP-1) 受体拮抗剂，可作为减肥后低血糖症（减肥手术的慢性并发症）的潜在疗法。 MBX 4291 被设计为长效、高效的 GLP-1 和葡萄糖依赖性胰岛素促泌多肽、受体共激动剂前体药物。
MBX Biosciences Inc简介
公司代码MBX
公司名称MBX Biosciences Inc
上市日期Sep 13, 2024
CEOMr. P. Kent Hawryluk
员工数量43
证券类型Ordinary Share
年结日Sep 13
公司地址11711 N. Meridian Street
城市CARMEL
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编46032
电话13179893100
网址https://mbxbio.com/
公司代码MBX
上市日期Sep 13, 2024
CEOMr. P. Kent Hawryluk
MBX Biosciences Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Salomon (Sam) Azoulay, M.D.
Dr. Salomon (Sam) Azoulay, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. P. Kent Hawryluk
Mr. P. Kent Hawryluk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Denike
Mr. Jim Denike
Senior Director - Investor Relations and Communications
Senior Director - Investor Relations and Communications
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Executive Chairperson of the Board
Executive Chairperson of the Board
--
--
Ms. Ora Pescovitz, M.D.
Ms. Ora Pescovitz, M.D.
Independent Director
Independent Director
--
--
Mr. Richard B. Bartram, CPA
Mr. Richard B. Bartram, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Lead Independent Director
Lead Independent Director
--
--
Mr. Edward T. (Ed) Mathers
Mr. Edward T. (Ed) Mathers
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Tiba Aynechi, Ph.D.
Dr. Tiba Aynechi, Ph.D.
Independent Director
Independent Director
--
--
Dr. Salomon (Sam) Azoulay, M.D.
Dr. Salomon (Sam) Azoulay, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. P. Kent Hawryluk
Mr. P. Kent Hawryluk
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Steven W. Ryder, M.D.
Dr. Steven W. Ryder, M.D.
Independent Director
Independent Director
--
--
Mr. Jim Denike
Mr. Jim Denike
Senior Director - Investor Relations and Communications
Senior Director - Investor Relations and Communications
--
--
Mr. Steven L. (Steve) Hoerter
Mr. Steven L. (Steve) Hoerter
Executive Chairperson of the Board
Executive Chairperson of the Board
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
14.81%
Wellington Management Company, LLP
10.74%
OrbiMed Advisors, LLC
8.91%
New Enterprise Associates (NEA)
8.05%
Deep Track Capital LP
4.87%
其他
52.61%
持股股东
持股股东
占比
Frazier Life Sciences Management, L.P.
14.81%
Wellington Management Company, LLP
10.74%
OrbiMed Advisors, LLC
8.91%
New Enterprise Associates (NEA)
8.05%
Deep Track Capital LP
4.87%
其他
52.61%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
23.75%
Private Equity
23.73%
Hedge Fund
17.07%
Venture Capital
13.68%
Investment Advisor
12.39%
Individual Investor
2.73%
Research Firm
0.22%
Bank and Trust
0.04%
Insurance Company
0.01%
其他
6.38%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
152
40.77M
90.80%
+4.25M
2025Q2
135
36.81M
110.11%
+2.26M
2025Q1
128
36.79M
110.24%
+3.57M
2024Q4
95
34.04M
101.87%
+3.71M
2024Q3
48
31.37M
98.32%
+31.37M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Frazier Life Sciences Management, L.P.
5.22M
11.68%
-765.91K
-12.80%
Sep 26, 2025
Wellington Management Company, LLP
4.82M
10.79%
+2.56M
+112.80%
Sep 30, 2025
OrbiMed Advisors, LLC
4.00M
8.95%
--
--
Sep 26, 2025
New Enterprise Associates (NEA)
3.61M
8.09%
--
--
Jun 30, 2025
Deep Track Capital LP
2.19M
4.9%
-830.34K
-27.50%
Jun 30, 2025
Norwest Venture Partners
2.14M
4.78%
--
--
Sep 26, 2025
The Vanguard Group, Inc.
1.04M
2.33%
+378.12K
+56.81%
Jun 30, 2025
Driehaus Capital Management, LLC
1.57M
3.52%
-7.30K
-0.46%
Jun 30, 2025
T. Rowe Price Associates, Inc.
1.30M
2.92%
+241.78K
+22.76%
Jun 30, 2025
MPM BioImpact LLC
1.29M
2.9%
+161.47K
+14.25%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.18%
ALPS Medical Breakthroughs ETF
0.36%
iShares Health Innovation Active ETF
0.29%
iShares Micro-Cap ETF
0.05%
Fidelity Enhanced Small Cap ETF
0.04%
iShares Russell 2000 Value ETF
0.02%
Global X Russell 2000 ETF
0.01%
iShares Russell 2000 ETF
0.01%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.18%
ALPS Medical Breakthroughs ETF
占比0.36%
iShares Health Innovation Active ETF
占比0.29%
iShares Micro-Cap ETF
占比0.05%
Fidelity Enhanced Small Cap ETF
占比0.04%
iShares Russell 2000 Value ETF
占比0.02%
Global X Russell 2000 ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
